Funding of Phase II SBIR Contract. N44 DA-12-2227

第二阶段 SBIR 合同的资金。

• 批准号: 8756304
• 负责人: Adam Hanina
• 金额: $ 99.75万
• 依托单位: AI CURE TECHNOLOGIES, LLC
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-11 至 2015-09-10
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8756304
• 关键词: Clinical Trials; Communication; Contractor; Development; Directly Observed Therapy; Effectiveness; Feedback; Funding; Intervention; Measures; Monitor; Outcome; Pharmaceutical Preparations; Phase; Research; Research Contracts; Small Business Innovation Research Grant; System; Technology; Work; improved; medication compliance

Under this Small Business Innovation Research (SBIR) Phase II project, "Automating Directly Observed Therapy as a Platform Technology," under Research Topic 139, the Contractor shall provide and evaluate the effectiveness and accuracy of a system for monitoring medication adherence in a treatment setting. In addition to monitoring, an intrinsic component of the system will be an integrated communication platform allowing for intervention and feedback with the user and a measure of the accuracy of the system. Following additional development work on the system, the Contractor will implement the AiView-HR ¿ system in a clinical trial with the objectives of (1) providing a measure of the accuracy of the system, and (2) demonstrating that the system improves medication adherence.

在小型企业创新研究(SBIR)第二阶段项目“将直接观察疗法自动化作为平台技术”下，在研究课题139项下，承包商应提供和评估用于监测治疗环境中的用药依从性的系统的有效性和准确性。除监测外，该系统的一个固有组成部分将是一个综合通信平台，以便与用户进行干预和反馈，并衡量该系统的准确性。在对系统进行额外的开发工作之后， 承包商将在临床试验中实施AiView-HR系统，目标是(1)提供系统准确性的衡量标准，以及(2)证明该系统改善了药物依从性。